DE60210752D1 - Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen - Google Patents

Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen

Info

Publication number
DE60210752D1
DE60210752D1 DE60210752T DE60210752T DE60210752D1 DE 60210752 D1 DE60210752 D1 DE 60210752D1 DE 60210752 T DE60210752 T DE 60210752T DE 60210752 T DE60210752 T DE 60210752T DE 60210752 D1 DE60210752 D1 DE 60210752D1
Authority
DE
Germany
Prior art keywords
inflammatory diseases
proteoglykan
treatment
pharmaceutical composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60210752T
Other languages
English (en)
Other versions
DE60210752T2 (de
Inventor
Theoharis C Theoharides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60210752D1 publication Critical patent/DE60210752D1/de
Publication of DE60210752T2 publication Critical patent/DE60210752T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60210752T 2001-01-30 2002-01-03 Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen Expired - Lifetime DE60210752T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/771,669 US6984667B2 (en) 1998-04-08 2001-01-30 Synergistic proteoglycan compositions for inflammatory conditions
US771669 2001-01-30
PCT/US2002/000476 WO2002060393A2 (en) 2001-01-30 2002-01-03 Proteoglycan compositions for treatment of inflammatory conditions

Publications (2)

Publication Number Publication Date
DE60210752D1 true DE60210752D1 (de) 2006-05-24
DE60210752T2 DE60210752T2 (de) 2007-04-12

Family

ID=25092582

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210752T Expired - Lifetime DE60210752T2 (de) 2001-01-30 2002-01-03 Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen

Country Status (7)

Country Link
US (7) US6984667B2 (de)
EP (1) EP1365777B1 (de)
AT (1) ATE323501T1 (de)
AU (1) AU2002239841A1 (de)
DE (1) DE60210752T2 (de)
ES (1) ES2261632T3 (de)
WO (1) WO2002060393A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220908A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Anti-inflammatory compositions for multiple sclerosis
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
DE10212502A1 (de) * 2002-03-20 2003-10-02 G O T Therapeutics Gmbh Verwendung von mindestens einem Flavonoid des Quercetins zur Erhöhung des Spiegels von nützlichen kurzkettigen Fettsäuren (SCFA) im unteren Intestinaltrakt
US20030229030A1 (en) * 2002-06-11 2003-12-11 Theoharides Theoharis C. Method of treating interleukin-6-mediated inflammatory diseases
US20040253296A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Food bar for treating musculoskeletal disorders
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US7485629B2 (en) * 2002-10-16 2009-02-03 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treatment of joint damage
US7326734B2 (en) * 2003-04-01 2008-02-05 The Regents Of The University Of California Treatment of bladder and urinary tract cancers
US7976880B2 (en) * 2003-06-04 2011-07-12 Ramaswamy Rajendran Pregnane glycoside compositions and Caralluma extract products and uses thereof
US20070185012A1 (en) * 2003-07-10 2007-08-09 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
ES2223291B1 (es) * 2003-08-06 2006-03-16 Bioiberica, S.A. Nuevo uso terapeutico de condroitin sulfato.
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US20050261367A1 (en) * 2004-03-29 2005-11-24 Howard Murad Methods for treating dermatological and other health-related conditions in a patient
US20050220912A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Anti-inflammatory composition for treating pelvic endometriosis
US20050220907A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Implanted medical devices with anti-inflammatory coatings
JP2005290331A (ja) * 2004-04-06 2005-10-20 Shinto Fine Co Ltd 抗アレルゲン組成物及びアレルゲン不活性化方法
GB0411166D0 (en) * 2004-05-19 2004-06-23 Bionovate Ltd Treatment for asthma and arthritis
CA2571394C (en) * 2004-06-30 2012-01-03 E-L Management Corp. Cosmetic compositions and methods comprising rhodiola rosea
US20080300198A1 (en) * 2004-08-09 2008-12-04 Kathleen Matt Olive Compositions and Methods for Treating Inflammatory Conditions
KR101154616B1 (ko) * 2004-12-31 2012-06-08 (주)아모레퍼시픽 캄페롤 및 퀘르세틴을 함유하는 히알루론산 생성 촉진용조성물
BRPI0610180A2 (pt) * 2005-05-24 2012-09-25 Wellgen Inc métodos para prevenir, para tratar, e para tratar ou controlar uma condição associada à inflamação
US9789149B2 (en) * 2005-07-19 2017-10-17 Creagri, Inc. Vegetation water composition for treatment of inflammatory skin conditions
WO2007064871A2 (en) * 2005-12-02 2007-06-07 Howard Murad Diagnostic and treatment regimen for achieving body water homeostasis
ITMI20061030A1 (it) 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
DE102006060953A1 (de) * 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
US20080227747A1 (en) * 2007-03-15 2008-09-18 Tabbiner Philip Composition and methods for treating or preventing degenerative joint and cardiovascular conditions
WO2008151107A2 (en) * 2007-06-01 2008-12-11 Massachusetts Institute Of Technology High-resolution flexural stage for in-plane position and out-of-plane pitch/roll alignment
US20090082738A1 (en) * 2007-09-24 2009-03-26 Vad Vijay B Natural Anti-Inflammatory Agents for Reducing Pain
EP2231136A1 (de) * 2007-12-12 2010-09-29 DSM IP Assets B.V. Zusammensetzungen mit hydroxytyrosol und chondroitin und ihre verwendung zur behandlung, begleitenden behandlung oder prävention von entzündlichen erkrankungen
EP2281008B1 (de) 2008-04-04 2017-01-04 University of Utah Research Foundation Alkylierte und sulfatierte hyaluronsäure, verfahren zu ihrer herstellung und ihre verwendung
CA2723315A1 (en) * 2008-04-30 2009-11-05 Ben-Gurion University Of The Negev Research And Development Authority Vascular delivery systems
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
US9889098B2 (en) * 2009-10-22 2018-02-13 Vizuri Health Sciences Llc Methods of making and using compositions comprising flavonoids
EP2688402B1 (de) 2011-03-23 2018-10-24 University of Utah Research Foundation Mittel zur behandlung bzw. prävention von harnwegsentzündungen
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US9295684B2 (en) * 2012-06-07 2016-03-29 Ming-Chen Lee Cream composition enhancing skin absorption of glucosamine
CA2947308A1 (en) 2013-05-09 2014-11-13 Zeenar Enterprises Pty Ltd Niacin formulation
SG10201801521QA (en) * 2013-09-30 2018-04-27 Sunstar Inc Anti-obesity composition
JP2016153384A (ja) * 2015-02-20 2016-08-25 花王株式会社 ウロプラキン発現促進剤
WO2018053111A1 (en) 2016-09-15 2018-03-22 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
US10729693B2 (en) * 2018-03-02 2020-08-04 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1273669A (en) * 1916-11-27 1918-07-23 Robert W Prittie Composition of matter.
US3067106A (en) * 1959-04-07 1962-12-04 Foundation For Prosthetic Res Skin treating method and composition
CA1036941A (en) * 1974-05-03 1978-08-22 Joseph Nastasi Anti-inflammatory preparation
US4265823A (en) * 1979-01-04 1981-05-05 Robert E. Kosinski Aurothiosteroids
GB8332265D0 (en) * 1983-12-02 1984-01-11 Biorex Laboratories Ltd Pharmaceutical compositions
US5110814A (en) * 1989-01-11 1992-05-05 Asta Pharma Ag Azelastine and its salts used to combat psoriasis
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5250529A (en) * 1990-02-08 1993-10-05 Kos Pharmaceuticals, Inc. Method alleviating migraine headache with mast cell degranulation blocking agents
DE4106026A1 (de) * 1991-02-26 1992-08-27 Plantamed Arzneimittel Gmbh Pharmazeutische zubereitungen enthaltend eine gallussaeureverbindung und/oder quercetin sowie verfahren zur isolierung dieser verbindungen
US5994357A (en) * 1991-11-05 1999-11-30 Theoharides; Theoharis C. Method of treatment for interstitial cystitis
EP0571597A4 (en) * 1991-11-15 1994-06-01 Arthro Res & Dev Corp Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
US5223257A (en) * 1992-03-11 1993-06-29 Vasu Arora Topical composition for relieving aches and pains
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
DK0674641T3 (da) * 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
US5648355A (en) * 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
IT1273742B (it) * 1994-08-01 1997-07-09 Lifegroup Spa Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5795905A (en) * 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5855884A (en) * 1995-11-27 1999-01-05 Kos Pharmaceuticals, Inc. Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker
US6020305A (en) * 1996-08-06 2000-02-01 Kos Pharmaceuticals, Inc. Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
US5843959A (en) * 1997-03-19 1998-12-01 University Of Florida Research Foundation, Inc. Methods and bicyclic polyamine compositions for the treatment of inflammation
JP2002501493A (ja) * 1997-04-22 2002-01-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｒｆアンタゴニストのチオフェノピリジン類
US7115278B2 (en) * 1998-04-08 2006-10-03 Theoharis C Theoharides Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US6391864B1 (en) * 1998-08-19 2002-05-21 Joint Juice, Inc. Food supplement containing a cartilage supplement
DE19839443A1 (de) * 1998-08-29 2000-03-02 Miklos Ghyczy Arnzneimittel mit entzündungshemmender Wirkung
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6136795A (en) * 1998-11-18 2000-10-24 Omni Nutraceuticals, Inc Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
US6492429B1 (en) * 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
US6696074B2 (en) * 2000-12-04 2004-02-24 Tei Biosciences, Inc. Processing fetal or neo-natal tissue to produce a scaffold for tissue engineering
US8163734B2 (en) * 2003-02-13 2012-04-24 Perttu J. Lindsberg Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses

Also Published As

Publication number Publication date
ATE323501T1 (de) 2006-05-15
DE60210752T2 (de) 2007-04-12
EP1365777A2 (de) 2003-12-03
US20050042312A1 (en) 2005-02-24
US20030104087A1 (en) 2003-06-05
US20020176902A1 (en) 2002-11-28
AU2002239841A1 (en) 2002-08-12
US20030099732A1 (en) 2003-05-29
WO2002060393B1 (en) 2003-11-27
US20030113392A1 (en) 2003-06-19
EP1365777B1 (de) 2006-04-19
WO2002060393A2 (en) 2002-08-08
US6641806B2 (en) 2003-11-04
ES2261632T3 (es) 2006-11-16
US6635625B2 (en) 2003-10-21
WO2002060393A3 (en) 2003-03-20
US6624148B2 (en) 2003-09-23
US6984667B2 (en) 2006-01-10
US6645482B2 (en) 2003-11-11
US20030104088A1 (en) 2003-06-05
US20040005355A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
DE60210752D1 (de) Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen
BR9803198A (pt) Composto, processos para preparar o mesmo e para combater fungo ou uma doença fúngica de plantas em um local, e, composição.
BR0013081A (pt) Pirimidino-2,4,6-trionas inibidoras de metaloproteinases
DE60131881D1 (de) Topische zusammensetzung enthaltend mindestens ein vitamin d oder vitamin d analogon und mindestens ein corticosteroid
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
BRPI0017535B8 (pt) composto de difenil-uréias substituídas com ômega-carbóxi-arilas
ATE478867T1 (de) Substituierte quinazolinone verbindungen
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BRPI0415758A (pt) combinações de substáncias ativas fungicidas sinergìsticas
BRPI0606893A2 (pt) absorvedores de uv de benzotriazol alterado de comprimentos de onda longos e usos dos mesmos
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
ECSP085573A (es) COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCOMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE TASA Y UN AGENTE ESTABILIZANTE
BRPI0911681B8 (pt) composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
BRPI0412871A (pt) combinações de substáncias ativas fungicidas
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
PT1070503E (pt) Composicoes compreendendo heparina de peso molecular muito reduzido
BRPI0409742A (pt) uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica
DE602006009259D1 (de) Pharmazeutische zusammensetzung mit einem organopoirkstoff
BRPI0414386A (pt) composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição
ES2096743T3 (es) Nuevas composiciones.
BR0208740A (pt) Sistema de camada termoabsorvente
BRPI0408499A (pt) solução aquosa estável de um fungicida de polieno

Legal Events

Date Code Title Description
8364 No opposition during term of opposition